US2018037577A1PendingUtilityA1
Inhibitors of jun n-terminal kinase
Est. expiryFeb 6, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Hing L. ShamRoy HomAndrei W. KonradiGary ProbstSimeon BowersAnh TruongR. Jeffrey NeitzJennifer SealyGergely Toth
A61P 37/08A61P 5/14A61P 35/04A61P 39/02A61P 9/10A61P 37/06A61P 7/00A61P 43/00A61P 37/02A61P 9/00A61P 7/06A61P 7/02A61P 7/10A61P 9/04A61P 3/10A61P 25/04A61P 31/04A61P 25/08A61P 35/00A61P 29/00A61P 25/00A61P 25/28A61P 31/06A61P 25/14A61P 25/16A61P 31/16A61P 27/02A61P 33/06A61P 25/06A61P 35/02A61P 25/32A61P 27/06A61P 1/16A61P 11/00A61P 11/06A61P 1/04A61P 1/18A61P 17/00A61P 13/12A61P 19/02A61P 1/00A61P 17/06A61P 19/10A61P 21/04A61P 21/02A61P 19/06A61P 11/16A61P 1/02C07D 409/04A61K 31/498C07D 471/04A61K 31/381A61K 31/401C07D 487/04A61K 31/4196A61K 31/4985C07D 409/14A61K 31/4709A61K 31/519A61K 31/433A61K 31/4245C07D 413/14C07D 417/14C07D 413/04A61K 31/4725C07D 417/04
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, C a , C b , Z, R 5 , W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound having a structure according to Formula (I):
or a salt or solvate thereof,
wherein
ring A is 5-membered heteroaryl comprising a sulfur atom, wherein the heteroaryl is optionally substituted with 1 or 2 substituents independently chosen from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, C 3 -C 10 -cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR 12 , SR 12 , NR 12 R 13 , C(O)R 14 , C(O)NR 12 R 13 , OC(O)NR 12 R 13 , C(O)OR 12 , NR 15 C(O)R 14 , NR 15 C(O)OR 12 , NR 15 C(O)NR 12 R 13 , NR 15 C(S)NR 12 R 13 , NR 15 S(O) 2 R 14 , S(O) 2 NR 12 R 13 , S(O)R 14 and S(O) 2 R 14 ,
wherein
R 12 , R 13 and R 15 are independently chosen from H, acyl, C 1 -C 6 -alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C 3 -C 8 cycloalkyl and 3- to 8-membered heterocycloalkyl, or R 12 and R 13 , together with the nitrogen atom to which they are bound form a 5- to to 7-membered heterocyclic ring; and
R 14 is chosen from acyl, C 1 -C 6 -alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C 3 -C 8 cycloalkyl and 3- to 8-membered heterocycloalkyl;
C a and C b are carbon atoms, which are adjacent to each other and are part of ring A;
Z is 5- or 6-membered heteroaryl, with the proviso that
(i) when ring A is thiophene, then Z is not a heteroaryl chosen from benzoimidazole, thiazole, and benzothiazole;
(ii) when ring A is thiazole, then Z is not benzoimidazole;
(iii) when ring A is thiophene, then Z is not substituted oxadiazole; and
(iv) when ring A is thiophene, then Z is not pyrimidinone;
R 5 is chosen from H, acyl, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl;
W is chosen from C 1 -C 4 alkylene, wherein the alkylene is optionally substituted with 1-4 substituents independently chosen from alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, C 3 -C 6 -cycloalkyl, 3- to 8-membered heterocycloalkyl, aryl, 5- or 6-membered heteroaryl, CN, halogen, OR 42 , SR 42 , NR 42 R 43 , C(O)R 44 , C(O)NR 42 R 43 , OC(O)NR 42 R 43 , C(O)OR 42 , NR 45 C(O)R 44 , NR 45 C(O)OR 42 , NR 45 C(O)NR 42 R 43 , NR 45 C(S)NR 42 R 43 , NR 45 S(O) 2 R 44 , S(O) 2 NR 42 R 43 , S(O)R 44 , and S(O) 2 R 44 ,
wherein
R 42 , R 43 and R 45 are members independently chosen from H, acyl, C 1 -C 6 -alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C 3 -C 8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R 42 and R 43 , together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; and
R 44 is independently chosen from acyl, C 1 -C 6 -alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C 3 -C 8 cycloalkyl and 3- to 8-membered heterocycloalkyl;
Cy is chosen from cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein the cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with 1-6 substituents independently chosen from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, haloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, CN, halogen, OR 52 , SR 52 , NR 52 R 53 , C(O)R 54 , C(O)NR 52 R 53 , OC(O)NR 52 R 53 , C(O)OR 52 , NR 55 C(O)R 54 , NR 55 C(O)OR 52 , NR 55 C(O)NR 52 R 53 , NR 55 C(S)NR 52 R 53 , NR 55 S(O) 2 R 54 , S(O) 2 NR 52 R 53 , S(O)R 54 and S(O) 2 R 54 ,
wherein
R 52 , R 53 and R 55 are independently chosen from H, acyl, C 1 -C 6 -alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C 3 -C 8 cycloalkyl and 3- to 8-membered heterocycloalkyl, wherein R 52 and R 53 , together with the nitrogen atom to which they are bound are optionally joined to form a 5- to 7-membered heterocyclic ring; and
R 54 is independently chosen from acyl, C 1 -C 6 -alkyl, 2- to 6-membered heteroalkyl, aryl, 5- or 6-membered heteroaryl, C 3 -C 8 cycloalkyl and 3- to 8-membered heterocycloalkyl.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.